PMV Pharmaceuticals Inc
NASDAQ:PMVP
Income Statement
Earnings Waterfall
PMV Pharmaceuticals Inc
Income Statement
PMV Pharmaceuticals Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(35)
|
(39)
|
(44)
|
(50)
|
(58)
|
(65)
|
(70)
|
(74)
|
(77)
|
(80)
|
(82)
|
(82)
|
(80)
|
(77)
|
(77)
|
(79)
|
(85)
|
(89)
|
(91)
|
(92)
|
(86)
|
|
| Selling, General & Administrative |
(11)
|
(13)
|
(17)
|
(20)
|
(22)
|
(24)
|
(25)
|
(25)
|
(25)
|
(25)
|
(25)
|
(25)
|
(24)
|
(23)
|
(22)
|
(21)
|
(27)
|
(26)
|
(25)
|
(24)
|
(16)
|
|
| Research & Development |
(24)
|
(25)
|
(27)
|
(31)
|
(36)
|
(41)
|
(45)
|
(49)
|
(52)
|
(55)
|
(58)
|
(58)
|
(56)
|
(54)
|
(55)
|
(58)
|
(59)
|
(63)
|
(67)
|
(68)
|
(70)
|
|
| Operating Income |
(35)
N/A
|
(39)
-12%
|
(44)
-13%
|
(50)
-15%
|
(58)
-16%
|
(65)
-12%
|
(70)
-7%
|
(74)
-6%
|
(77)
-4%
|
(80)
-4%
|
(82)
-3%
|
(82)
0%
|
(80)
+3%
|
(77)
+4%
|
(77)
0%
|
(79)
-3%
|
(85)
-8%
|
(89)
-4%
|
(91)
-3%
|
(92)
-1%
|
(86)
+6%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
4
|
6
|
8
|
10
|
11
|
12
|
12
|
12
|
11
|
10
|
9
|
7
|
6
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(34)
N/A
|
(39)
-13%
|
(44)
-13%
|
(50)
-14%
|
(58)
-16%
|
(65)
-12%
|
(69)
-7%
|
(72)
-5%
|
(73)
-1%
|
(74)
-1%
|
(74)
0%
|
(73)
+2%
|
(69)
+5%
|
(65)
+6%
|
(65)
+0%
|
(68)
-4%
|
(75)
-11%
|
(79)
-6%
|
(83)
-5%
|
(85)
-2%
|
(80)
+6%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
16
|
16
|
16
|
18
|
2
|
2
|
2
|
|
| Income from Continuing Operations |
(34)
|
(39)
|
(44)
|
(50)
|
(58)
|
(65)
|
(69)
|
(72)
|
(73)
|
(74)
|
(74)
|
(73)
|
(69)
|
(65)
|
(49)
|
(51)
|
(59)
|
(61)
|
(81)
|
(83)
|
(78)
|
|
| Net Income (Common) |
(34)
N/A
|
(39)
-13%
|
(44)
-13%
|
(50)
-14%
|
(58)
-16%
|
(65)
-12%
|
(69)
-7%
|
(72)
-5%
|
(73)
-1%
|
(74)
-1%
|
(74)
0%
|
(73)
+2%
|
(69)
+5%
|
(65)
+6%
|
(49)
+25%
|
(51)
-5%
|
(59)
-14%
|
(61)
-4%
|
(81)
-33%
|
(83)
-2%
|
(78)
+6%
|
|
| EPS (Diluted) |
-0.77
N/A
|
-0.86
-12%
|
-0.98
-14%
|
-1.11
-13%
|
-1.28
-15%
|
-1.43
-12%
|
-1.52
-6%
|
-1.59
-5%
|
-1.61
-1%
|
-1.62
-1%
|
-1.62
N/A
|
-1.47
+9%
|
-1.44
+2%
|
-1.26
+12%
|
-0.97
+23%
|
-1
-3%
|
-1.14
-14%
|
-1.18
-4%
|
-1.56
-32%
|
-1.56
N/A
|
-1.48
+5%
|
|